하이로닉 인터내셔널 웹사이트로 이동합니다.
인터내셔널 웹사이트에는 수출용 제품으로 대한민국에서 허가하지 않은 장비 및 서비스 내용을 포함하고 있습니다. 해당 내용은 대한민국의 의료기기 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC INTL. website.
The Intrrnation Web Site contains equipment and services that are not authorized by the Republic of Korea These contents are not subject to review and regulation of medical devices in Korea.
하이로닉 US 웹사이트로 이동합니다.
US 웹사이트의 내용은 "FDA"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC US website.
The contents of the US web page are about product information of items approved for "FDA". They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
하이로닉 EU 웹사이트로 이동합니다.
EU 웹사이트의 내용은 "CE MDD 또는 CE MDR"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC EU website.
The contents of the EU(European) web page are about product information of items approved for "CEMDD or CEMDR" in EU countries. They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
HIRONIC Co., Ltd. (CEO: Jinwoo Lee), a global manufacturer and supplier of aesthetic medical devices, announced that its HIFU-based lifting system, NEW DOUBLO 2.0 (known domestically as V-RO Advance), has obtained official import approvals from key regulatory authorities in the Middle East, including the Ministry of Health and Prevention (MOHAP) of the United Arab Emirates, the Ministry of Public Health (MOPH) of Qatar, and the Saudi Food and Drug Authority (SFDA).
NEW DOUBLO 2.0 is the latest model in HIRONIC’s flagship DOUBLO HIFU series, incorporating advanced focusing technology and precise energy control algorithms to deliver stable and consistent treatment outcomes. The platform supports a versatile configuration of treatment handpieces, including HIFU, RF microneedling (RM), and RF, enabling physicians to address a wide range of clinical needs such as skin lifting, elasticity improvement, pore refinement, and skin tone enhancement. As a result, demand for the system continues to grow rapidly across global markets.
In recent months, HIRONIC has conducted on-site clinical training and operational education programs for NEW DOUBLO 2.0 in both the UAE and Saudi Arabia. These programs provided local medical professionals with comprehensive instruction, ranging from in-depth explanations of core technologies to hands-on training sessions, and received strong interest and positive feedback from clinics and practitioners in the region.
Following the latest import approvals, HIRONIC plans to further expand collaboration with regional partners while strengthening communication and engagement with the Middle Eastern market.
“Demand for premium aesthetic treatments is growing rapidly across the Middle East,” said a representative from HIRONIC. “With consecutive import approvals in the UAE, Saudi Arabia, and Qatar, we aim to actively highlight the technological competitiveness of NEW DOUBLO 2.0 and further solidify our brand presence in the region.”
Meanwhile, HIRONIC continues to expand global regulatory approvals for NEW DOUBLO 2.0, including ongoing processes in the United States (FDA) and Indonesia (KEMENKES RI), as part of its broader strategy to strengthen its global footprint.
